drugset / Trial / NCT02624141
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units \[IU\]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.
Timeline
- Start
- 2006-04
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 30000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 60000 iu | Subcutaneous |